Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft by ¹⁸F-FLT MicroPET/CT Imaging

Figure 2

¹⁸F-FLT microPET/CT imaging of U87MG tumor-bearing mice. (a) Representative decay-corrected whole-body coronal microPET/CT images at 1.0 h after intravenous injection of ¹⁸F-FLT (11.1 MBq per mouse) on days 0, 1, 3, 7, and 13 after treatment was initiated. (b) The ratios of %ID/g_max of tumor to the contralateral muscle (T/M) in the Sunitinib and control groups based on quantitative ROIs analysis from ¹⁸F-FLT microPET/CT on days 0, 1, 3, 7, and 13 after treatment. The tumors are indicated by arrows. ^∗∗𝑃<0.01, within the Sunitinib group, compared to day 0. ^■■𝑃<0.01, between the Sunitinib group and the control group.

(a)

(b)